Analysts expect that Eli Lilly And Co (NYSE:LLY) will report sales of $6.10 billion for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Eli Lilly And Co’s earnings. The lowest sales estimate is $6.06 billion and the highest is $6.15 billion. Eli Lilly And Co posted sales of $5.66 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.8%. The company is expected to announce its next quarterly earnings report before the market opens on Tuesday, November 6th.
According to Zacks, analysts expect that Eli Lilly And Co will report full-year sales of $24.48 billion for the current fiscal year, with estimates ranging from $24.45 billion to $24.51 billion. For the next year, analysts forecast that the company will report sales of $25.04 billion, with estimates ranging from $24.93 billion to $25.12 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Eli Lilly And Co.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.11 earnings per share.
Several analysts recently weighed in on LLY shares. TheStreet cut shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a report on Friday, August 24th. SunTrust Banks boosted their target price on shares of Eli Lilly And Co from $105.00 to $123.00 and gave the company a “buy” rating in a report on Monday, October 1st. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, September 28th. JPMorgan Chase & Co. set a $117.00 target price on shares of Eli Lilly And Co and gave the company an “overweight” rating in a report on Wednesday, September 26th. Finally, Morgan Stanley boosted their target price on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $109.80.
NYSE:LLY opened at $111.92 on Monday. The firm has a market capitalization of $120.20 billion, a P/E ratio of 22.25, a P/E/G ratio of 1.82 and a beta of 0.29. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $116.61. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.
In other news, major shareholder Lilly Endowment Inc sold 185,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total value of $17,025,550.00. Following the completion of the transaction, the insider now owns 121,631,601 shares of the company’s stock, valued at approximately $11,193,756,240.03. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 7,000 shares of Eli Lilly And Co stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the completion of the transaction, the senior vice president now directly owns 45,224 shares of the company’s stock, valued at approximately $5,184,479.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,960,271 shares of company stock worth $199,950,452. Company insiders own 0.11% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $114,000. Legacy Advisors LLC raised its position in shares of Eli Lilly And Co by 118.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares during the last quarter. Fort L.P. purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $121,000. Finally, Financial Management Professionals Inc. purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $128,000. 76.38% of the stock is owned by hedge funds and other institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.